Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?

References

• Rosenbach M, Werth VP. Dermatologic therapeutics: thalidomide. A practical guide. Dermatol Ther. 2007;20:175–86
   Google Scholar
• Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254–73
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options. Part I. J Am Acad Dermatol. 2011;65:e179–93
   PubMedGoogle Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options. Part II. J Am Acad Dermatol. 2011;65:e195–213
   PubMedGoogle Scholar
• Callen JP. Management of ‘refractory’ skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. 2005;19:767–84
   Google Scholar
• Kuhn A, Lehmann P, Ruzicka T. Cutaneous Lupus Erythematosus. Heidelberg: Springer-Verlag, 2004. p 53–8
   Google Scholar
• Tan EM, Cohen AS, Fries JF, et al. The 1982 revisited criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7
   PubMed Web of Science ®Google Scholar
• Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983;108:461–6
   PubMed Web of Science ®Google Scholar
• Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol. 1993;11:487–93
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol. 1997;36:353–9
   PubMedGoogle Scholar
• Sato EI, Assis LS, Lourenzi VP, Andrade LE. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras. 1998;44:289–93
   PubMedGoogle Scholar
• Duong DJ, Spiegel T, Moxley RT, Gaspari AA. American experience with low-dose thalidomide therapy of severe cutaneous lupus erythematosus. Arch Dermatol. 1999;135:1079–87
   PubMed Web of Science ®Google Scholar
• Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000;39:218–22
   PubMed Web of Science ®Google Scholar
• Ordi-Ros J, Cortés F, Cucurull E, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol. 2000;27:1429–33
   PubMed Web of Science ®Google Scholar
• Housman TS, Jorizzo JL, McCarty MA, et al. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. 2003;139:50–4
   PubMedGoogle Scholar
• Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118:246–50
   PubMed Web of Science ®Google Scholar
• Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus. 2005;14:434–9
   PubMed Web of Science ®Google Scholar
• Briani C, Zara G, Rondinone R, et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology. 2004;62:2288–90
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus prognostic factors of clinical outcome. Br J Dermatol. 2012;166:616–23
   PubMed Web of Science ®Google Scholar
• Frankel HC, Sharon VR, Vleugels RA, et al. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol. 2013;52:1407–9
   PubMedGoogle Scholar
• Zara G, Ermani M, Rondinone R, et al. Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry. 2008;79:1258–61
   PubMed Web of Science ®Google Scholar
• Flageul B, Wallach D, Cavelier-Balloy B, et al. Thalidomide and thrombosis. Ann Dermatol Venereol. 2000;127:171–4
   PubMed Web of Science ®Google Scholar
• Llambrich A, Romero D, Iranzo P, et al. Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide. J Eur Acad Dermatol Venerol. 2007;21:136–7
   Google Scholar
• Piette JC, Sbai A, Francès C. Warning: thalidomide-related trombotic risk potentially concerns patients with lupus. Lupus. 2002;11:67–70
   PubMed Web of Science ®Google Scholar
• Olivier-Abbal P, Teisseyre A-C, Motastruc J-L. Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database. Med Oncol. 2013;30:733–41
   PubMed Web of Science ®Google Scholar
• Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009;145:303–6
   Google Scholar
• Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol. 2012;66:571–82
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012;14:R265
   Google Scholar